The High Throughput Screening Facility (HTSF) has developed during the previous five years to meet a need identified for high throughput capabilities and a central resource for multiple areas of translational research. The HTSF provides screening services, including the instrumentation and expertise to develop assays, execute siRNA and small molecule screens, and support for follow-up and secondary assay development and execution. In addition, the HTSF resources are available to clinical investigators to develop and implement clinical correlate assays for clinical trials and population science studies. The automation and detection instrumentation is available to all Fox Chase Cancer Center (FGGG) researchers, providing new technologies to investigators. Instrumentation and resources available from the HTSF include: automation compatible with 96 and 384 well screening platforms, the human genome siRNA library (Thermo-Fisher Dharmacon), and small molecule libraries (approx 50,000 compounds). Duhng its period as a developing facility the HTSF has acquired resources and reagents, initiated procedures for screen execution and provided assay services and screening support. In GY 2009, the HTSF provided support to 19 peer-reviewed, funded investigators, from all five of the Center's CCSG Research Programs (Section V). This user base has developed due to the strong institutional support provided by FCCC, including $776,808 for start-up equipment, as well as $1,454,952 in operating costs (FY2005-present). This has enabled the Facility to charge back Principal Investigators, (Pis) at reduced rates to enhance usage. The combination of equipment, expertise and subsidization has converged to create a community of screeners and translational scientists by initiating collaborative relationships among PI laboratories as well as between facilities, while in the process creating additional demand for HTSF support. The HTSF is a unique resource, as it combines services to a diverse group of investigators and collaboration among multiple, facilities. This allows the HTSF to act as a hub for translational science by making the most of the Center's resources in high throughput technology, traditional benchwork and clinical approaches.

Public Health Relevance

The HTSF provides a suite of services designed to accelerate the identification of new tools and therapeutic targets for cancer. Discoveries made through utilization of the screening and assay development tools provided by the HTSF will impact areas such as development of innovative probes for basic research, biomarker discovery and novel therapeutic approaches.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fox Chase Cancer Center
United States
Zip Code
Peri, Suraj; Caretti, Elena; Tricarico, Rossella et al. (2017) Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. Oncotarget 8:17628-17642
Reese, Jennifer Barsky; Bober, Sharon L; Daly, Mary B (2017) Talking about women's sexual health after cancer: Why is it so hard to move the needle? Cancer 123:4757-4763
Christian, Allison H; O'Malley, Denalee; Barac, Ana et al. (2017) Cardiovascular risk and communication among early stage breast cancer survivors. Patient Educ Couns 100:1360-1366
Jiang, Pengtao; Li, Yueran; Poleshko, Andrey et al. (2017) The Protein Encoded by the CCDC170 Breast Cancer Gene Functions to Organize the Golgi-Microtubule Network. EBioMedicine 22:28-43
Stepanova, Dina S; Semenova, Galina; Kuo, Yin-Ming et al. (2017) An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis. Cancer Res 77:5026-5038
Heckman, Carolyn J; Kloss, Jacqueline D; Feskanich, Diane et al. (2017) Associations among rotating night shift work, sleep and skin cancer in Nurses' Health Study II participants. Occup Environ Med 74:169-175
Cheung, Mitchell; Testa, Joseph R (2017) BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res 6:270-278
Gerson, James N; Skariah, Sam; Denlinger, Crystal S et al. (2017) Perspectives of HER2-targeting in gastric and esophageal cancer. Expert Opin Investig Drugs 26:531-540
Kruger, Warren D (2017) Cystathionine ?-synthase deficiency: Of mice and men. Mol Genet Metab 121:199-205
Jaffe, Eileen K (2017) New protein structures provide an updated understanding of phenylketonuria. Mol Genet Metab 121:289-296

Showing the most recent 10 out of 1165 publications